Skip to main content

Lenvatinib: A Review in Refractory Thyroid Cancer

Targeted Oncology volume 11, pages 115–122 (2016)Cite this article

Abstract

Lenvatinib (Lenvima®) is an oral, multi-targeted tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, fibroblast growth factor receptors 1, 2, 3 and 4, platelet-derived growth factor receptor alpha, and RET and KIT signalling networks, which are implicated in tumour growth and maintenance. In the EU and USA, lenvatinib is indicated for the treatment of locally recurrent or metastatic progressive, radioiodine-refractory differentiated thyroid cancer (RR-DTC). This approval was based on the results of the randomized, double-blind, multinational, phase 3 SELECT study, in which lenvatinib significantly improved median progression-free survival (PFS) and overall response rate compared with placebo in patients with RR-DTC. The PFS benefit with lenvatinib was seen in all pre-specified subgroups, including patients who had received either one or no prior VEGF-targeted therapy. Moreover, the PFS benefit with lenvatinib was maintained regardless of BRAF or RAS mutation status. The safety and tolerability profile of lenvatinib in SELECT was consistent with that of other VEGF/VEGF receptor-targeted therapies and was mostly manageable. Hypertension was the most common treatment-related adverse event in lenvatinib-treated patients, but only infrequently led to discontinuation of the drug. Although not collected in SELECT, information on quality of life would be useful in assessing the overall impact of therapy on the patient. This notwithstanding, the data which are available indicate that lenvatinib is an effective and generally well-tolerated treatment option for patients with RR-DTC. Lenvatinib, therefore, offers an acceptable alternative to sorafenib — currently, the only other TKI approved for this indication.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Cancer ResearchUK. Thyroid cancer incidence in Europe and worldwide. http://www.cancerresearchuk.org. Accessed 4 Sep 2015.

  2. EUCAN cancer factsheet: thyroid cancer. http://eco.iarc.fr. Accessed 4 Sep 2015.

  3. SEER stat fact sheets: thyroid cancer http://seer.cancer.gov. Accessed 4 Sep 2015.

  4. Jasim S, Ozsari L, Habra MA. Multikinase inhibitors use in differentiated thyroid carcinoma. Biol Tar Ther. 2014;8:281–91.

    Google Scholar 

  5. Worden F. Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer. Ther Adv Med Oncol. 2014;6(6):267–79.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  6. Brierley JD. Update on external beam radiation therapy in thyroid cancer. J Clin Endocrinol Metab. 2011;96(8):2289–95.

    CAS  Article  PubMed  Google Scholar 

  7. Busaidy NL, Cabanillas ME. Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res. 2012. doi:10.1155/2012/618985.

    PubMed  PubMed Central  Google Scholar 

  8. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–9.

    CAS  Article  PubMed  Google Scholar 

  9. Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91(2):498–505.

    CAS  Article  PubMed  Google Scholar 

  10. Alonso-Gordoa T, Diez JJ, Duran M, et al. Advances in thyroid cancer treatment: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7(1):22–38.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. Wang E, Karedan T, Perez CA. New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond. Anti-Cancer Drugs. 2015;26(7):689–97.

    CAS  Article  PubMed  Google Scholar 

  12. Gómez-Sáez J-M. Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer. Anti Cancer Agents Med Chem. 2013;13(3):483–95.

    Google Scholar 

  13. Klein M, Vignaud JM, Hennequin V, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2001;86(2):656–8.

    CAS  Article  PubMed  Google Scholar 

  14. Salajegheh A, Smith RA, Kasem K, et al. Single nucleotide polymorphisms and mRNA expression of VEGF-A in papillary thyroid carcinoma: potential markers for aggressive phenotypes. Eur J Surg Oncol. 2011;37(1):93–9.

    CAS  Article  PubMed  Google Scholar 

  15. Yu XM, Lo CY, Lam AK, et al. Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann Surg. 2008;247(3):483–9.

    Article  PubMed  Google Scholar 

  16. Schlumberger M, Sherman SI. Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol. 2012;166:5–11.

    CAS  Article  PubMed  Google Scholar 

  17. Fallahi P, Ferrari SM, Mazzi V, et al. Personalization of targeted therapy in advanced thyroid cancer. Curr Genomics. 2014;15:190–202.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–30.

    Article  PubMed  Google Scholar 

  19. Bayer Pharma AG. Nexavar 200 mg film-coated tablets. EU summary of product characteristics. 2015. http://www.ema.europa.eu. Accessed 3 Sep 2015.

  20. Bayer HealthCare Pharmaceuticals Inc. Nexavar (sorafenib) tablets, oral. US prescribing information. 2015. http://www.accessdata.fda. gov. Accessed 3 Sep 2015.

  21. Eisai Europe Ltd. Lenvima 4mg hard capsules: summary of product characteristics. 2015. http://www.ema.europa.eu. Accessed 17 Aug 2015.

  22. Eisai Inc. Lenvima (lenvatinib) capsules, for oral use: US prescribing information. 2015. http://www.lenvima.com. Accessed 17 Aug 2015.

  23. Eisai Co. Ltd. Eisai receives approval in Japan for anticancer agent Lenvima® (lenvatinib mesylate) as treatment for unresectable thyroid cancer [news release]. 2015. http://www.eisai.com. Accessed 3 Sep 2015.

  24. Scott LJ. Lenvatinib: first global approval. Drugs. 2015;75(5):553–60.

    CAS  Article  PubMed  Google Scholar 

  25. Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (E7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014. doi:10.1155/2014/638747.

    PubMed  PubMed Central  Google Scholar 

  26. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis. A crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2011;2(12):1097–105.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Okamoto K, Ikemori-Kawada M, Jestel A, et al. Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. ACS Med Chem Lett. 2015;6(1):89–94.

    CAS  Article  PubMed  Google Scholar 

  28. Shumaker RC, Zhou M, Ren M, et al. Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers. Cancer Chemother Pharmacol. 2014;73(6):1109–17.

    CAS  Article  PubMed  Google Scholar 

  29. Shumaker R, Aluri J, Fan J, et al. Effects of ketoconazole on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers. Clin Pharmacol Drug Dev. 2015;4(2):155–60.

    CAS  Article  PubMed  Google Scholar 

  30. Shumaker RC, Aluri J, Fan J, et al. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. ClinDrug Investig. 2014;34(9):651–9.

    CAS  Google Scholar 

  31. Cabanillas ME, Schlumberger M, Jarzab B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer. 2015;121(16):2749–56.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  32. Eisai Inc. Evaluating the safety and efficacy of oral E7080 in medullary and iodine-131 refractory, unresectable differentiated thyroid cancers, stratified by histology. 2014. https://clinicaltrials.gov/ct2/show/NCT00784303. Accessed 1 Nov 2015.

  33. Eisai Inc. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of lenvatinib (E7080) in 131I-refractory differentiated thyroid cancer. 2014. https://clinicaltrials.gov/ct2/show/NCT01321554. Accessed 23 Oct 2015.

  34. Robinson B, Schlumberger M, Wirth L, et al. Characterization of tumor size changes over time from the Phase 3 Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid (SELECT) [abstract no. 1031P]. In: European Society for Medical Oncology Congress. 2014.

  35. Brose MS, Schlumberger M, Tahara M, et al. Effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT [abstract no. 6048]. J Clin Oncol. 2015;33(Suppl).

  36. Guo M, Sherman S, Wirth L, et al. Overall survival gain with lenvatinib vs. placebo in radioactive iodine refractory differentiated thyroid cancer (RR-DTC): an updated analysis [abstract]. In: European Cancer Congress. 2015.

  37. Robinson B, Schlumberger M,Wirth L, et al. Open-label extension phase outcomes of the phase 3 Select trial of lenvatinib in patients with 131I-refractory differentiated thyroid cancer [abstract no. OR44]. In: 97th Annual Meeting of the Endocrine Society. 2015.

  38. Launay-Vacher V, Deray G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anti-Cancer Drugs. 2009;20(1):81–2.

    CAS  Article  PubMed  Google Scholar 

  39. Eisai Inc. An expanded access program with lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer. 2015. https://clinicaltrials.gov/ct2/show/NCT02211222. Accessed 23 Oct 2015.

  40. Center for Drug Evaluation and Research. Application number: 206947Orig1s000. Medical review(s). 2015. http://www.accessdata.fda.gov. Accessed 1 Sep 2015.

  41. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–28.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  42. Tremblay G, Li X, Abouzaid S, et al. Number-needed-to-treat (NNT) analysis of therapies in radioiodine-refractory differentiated thyroid cancer (RR-DTC) using indirect comparison [abstract]. In: 15th International Thyroid Congress and 85th Annual Meeting of the American Thyroid Association. 2015.

  43. Gruber JJ, Dimitrios CA. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist. 2015;20(2):113–26.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13:897–905.

    CAS  Article  PubMed  Google Scholar 

  45. Zhao Y. Lenvatinib in the management of differentiated thyroid cancer. 2015. http://targetedonc.com. Accessed 27 Oct 2015.

  46. Schlumberger M, Jarzab B, Cabanillas ME, et al. A phase 2 trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC). Clin Cancer Res. 2015. doi:10.1158/1078-0432.CCR-15-1127.

    PubMed  Google Scholar 

  47. Takahashi S, Tahara M, Kiyota N, et al. Phase II study of lenvatinib, a multitargeted tyrosine kinase inhibitor, in patients with all histologic subtypes of advanced thyroid cancer (differentiated, medullary, and anaplastic) [abstract no. 995PD]. In: European Society for Medical Oncology Congress. 2014.

  48. Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18. doi:10.1186/2045-824X-6-18.

  49. Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008;122(3):664–71.

    CAS  Article  PubMed  Google Scholar 

  50. Okamoto K, Kodama K, Takase K, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013;340(1):97–103.

    CAS  Article  PubMed  Google Scholar 

  51. Matsui J, Funahashi Y, Uenaka T, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lungmetastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008;14(17):5459–65.

    CAS  Article  PubMed  Google Scholar 

  52. Shumaker R, Aluri J, Fan J, et al. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers. Int J Clin Pharmacol. 2014;52(4):284–91.

    CAS  Article  Google Scholar 

  53. Dubbelman AC, Rosing H, Nijenhuis C, et al. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas. Investig New Drugs. 2015;33(1):233–40.

    CAS  Article  Google Scholar 

Download references

Acknowledgments

During the peer review process, the manufacturer of lenvatinib was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    James E. Frampton

Authors
  1. James E. Frampton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James E. Frampton.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflicts of Interest

James Frampton is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

The manuscript was reviewed by: A. Antonelli, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; C. Perez, Department of Medicine, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA; J Sáez, Endocrinology and Nutrition Service, University Hospital of Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Frampton, J.E. Lenvatinib: A Review in Refractory Thyroid Cancer. Targ Oncol 11, 115–122 (2016). https://doi.org/10.1007/s11523-015-0416-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-015-0416-3

Keywords

  • Thyroid Cancer
  • Sorafenib
  • Sunitinib
  • Papillary Thyroid Cancer
  • Pazopanib